Autolus Therapeutics (NASDAQ: AUTL) — Perfil da empresa, notícias e dados financeiros
Autolus Therapeutics develops next-generation T cell therapies for cancer treatment, aiming to improve clinical outcomes for patients.
Autolus Therapeutics
Autolus Therapeutics (NASDAQ:AUTL) is a biopharmaceutical company focused on the development and commercialization of next-generation programmed T cell therapies for the treatment of cancer. The company's pioneering work in CAR T cell therapy, aimed at harnessing the power of patients' immune systems to combat cancer, positions it at the forefront of cell and gene therapy. Autolus Therapeutics is committed to advancing a diverse portfolio of treatment candidates, with a primary objective of delivering life-changing benefits to patients facing serious diseases. Through innovative research and strategic partnerships, the company aims to improve clinical outcomes and fundamentally alter the cancer treatment landscape.
Resumo
Operações
Produtos e/ou serviços de Autolus Therapeutics
- Obe-cel (AUTO1): A CAR T-cell therapy aimed at treating adult acute lymphoblastic leukemia with a focus on reducing toxicity.
- AUTO1/22: A dual-targeting CAR T-cell therapy designed for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- AUTO3: A dual-targeting CAR T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia, emphasizing safety and efficacy.
- AUTO4: A T-cell receptor (TCR) therapy targeting TRBC1 for patients with T cell lymphomas, exploring a novel approach in cancer treatment.
- AUTO6: A CAR T-cell therapy focused on the treatment of solid tumors, aiming to expand the applicability of CAR T technology beyond hematological malignancies.
equipe executiva do Autolus Therapeutics
- Christian Martin ItinCEO & Director
- Martin PuleFounder, Senior VP & Chief Scientific Officer
- Robert F. DolskiSenior VP & CFO
- Christopher VannSenior VP & COO
- Patrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer
- Miranda NevilleSenior VP & Chief Technology Officer
- Alex DriggsSenior VP of Legal Affairs & General Counsel and Secretary
- Alexander SwanSenior VP & Chief Human Resources Officer
- Christopher WilliamsSenior VP & Chief Business Development Officer
- Matthias WillSenior VP & Chief Development Officer
Últimas notícias sobre a Autolus Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Autolus Therapeutics, em USD.
- Cap. de mercado
- 433,8 mi
- Receita (TTM)
- 117,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- -238.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 75,6 mi | -281,4 mi | -288,2 mi | |
| 10,1 mi | -241,4 mi | -220,7 mi | |
| 1,7 mi | -179,7 mi | -208,4 mi | |
| 6,2 mi | -142,9 mi | -148,8 mi |